Drugs Made In America Acquisition Corp. — Form 8-K

Drugs Made In America Acquisition Corp. (DMAA, a $234.6M public SPAC) has executed an amended merger agreement to acquire Power Analytics Global Corp. (PAGC), a private AI/analytics company, for a fixed Closing Valuation of US$2,850,000,000 in Domesticated DMAA Common Shares (not exceeding 265,116,279 shares at Reference Price ≥US$10.75). The merger includes PAGC's pending acquisition of APQC Inc. and UltraSolar IP. Closing conditions include completion of the APQC acquisition by December 31, 2026, delivery of a fairness opinion, minimum available closing cash of US$15,000,000, and satisfaction of Nasdaq listing requirements. The deal involves affiliated parties (BV Advisory Partners, LLC holds ≥40% sponsor economics and common principal ownership with PAGC). Outside date for closing is April 29, 2027.